Losartan Does Not Increase Cancer Risk and Should NOT Be Discontinued in Patients with Active Malignancy
Losartan is safe to continue in cancer patients and does not increase cancer risk. In fact, emerging evidence suggests losartan may provide anti-tumor benefits by remodeling the tumor microenvironment, though this should not be the primary reason for prescribing it.
Evidence on Cancer Risk
No Increased Cancer Incidence
The FDA label for losartan demonstrates no carcinogenic effect in long-term animal studies at doses providing 160-fold higher systemic exposure than standard human dosing 1. Large-scale clinical trials confirm this safety profile in humans.
A comprehensive meta-analysis of 15 randomized controlled trials involving 138,769 participants found no excess cancer risk with ARB therapy compared to controls (OR 1.00,95% CI 0.95-1.04) 2. This included no increase in lung, prostate, or breast cancer, or overall cancer deaths. Specifically for losartan, one large case-control study in diabetic patients actually showed a protective effect (OR 0.78,95% CI 0.63-0.97) 3.
Cardioprotection in Cancer Patients Takes Priority
Major cardio-oncology guidelines explicitly recommend ACE inhibitors and ARBs (including losartan) for cardioprotection during cancer treatment 4, 5. These medications are recommended to:
- Prevent chemotherapy-induced cardiotoxicity (particularly with anthracyclines and trastuzumab)
- Manage hypertension during cancer therapy
- Treat left ventricular dysfunction that develops during treatment
The guidelines make no mention of discontinuing ARBs due to cancer concerns 4, 5. This is telling—if there were genuine cancer risk, cardio-oncology guidelines would address it.
Potential Anti-Tumor Effects (Emerging Evidence)
While not yet standard of care, multiple recent studies suggest losartan may actually enhance cancer treatment efficacy:
- Ovarian cancer: Losartan improved chemotherapy delivery, reduced ascites, and patients on angiotensin system inhibitors had 30 months longer overall survival 6, 7
- Pancreatic cancer: Losartan reduced immunosuppression, decreased regulatory T-cells, and improved pathologic response rates when combined with chemotherapy 8
- Breast cancer: Losartan combined with radiotherapy increased tumor control and inhibited lung metastases 9
- Colorectal cancer: Losartan inhibited tumor growth and reduced metastasis in preclinical models 10
The mechanism appears to involve tumor microenvironment normalization—reducing fibrosis, improving vascular perfusion, decreasing hypoxia, and enhancing drug delivery and immune cell infiltration.
Clinical Recommendation Algorithm
For patients with cancer currently on losartan:
- Continue losartan without interruption
- Monitor blood pressure and renal function as per standard practice 1
- Watch for hyperkalemia, especially if on other potassium-sparing agents 1
For cancer patients with cardiovascular indications for ARBs:
- Initiate or continue ARB therapy (losartan or other ARBs) as clinically indicated
- Prioritize cardioprotection during cardiotoxic chemotherapy (anthracyclines, trastuzumab) 4
- Manage treatment-related hypertension with ARBs as first-line options 5
The only contraindication remains pregnancy (discontinue immediately if pregnancy detected) 1.
Important Caveats
- One recent phase 3 trial (AFPAC) showed no benefit of adding losartan to chemotherapy in advanced pancreatic cancer 11, suggesting benefits may be context-dependent
- The anti-tumor effects are investigational and should not be the primary reason for prescribing losartan
- Standard monitoring for ARB therapy applies: renal function, potassium, blood pressure 1
- Volume depletion should be corrected before initiating losartan in cancer patients who may be receiving diuretics 1
Bottom line: There is no evidence-based reason to discontinue losartan in cancer patients, and strong cardio-oncology guideline support for continuing ARBs during cancer treatment.